Hemotune is a company headquartered in Germany. Brouky records 4 investors associated with the company.
Hemotune develops an extracorporeal blood‑purification platform called HemoSystem that uses magnetic nanoparticles to selectively remove previously inaccessible biomolecules from blood. The technology is intended initially for treatment of uncontrolled immune reactions such as septic shock and may be applicable to other indications.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.